The Therapeutic Role of Soluble Adenylyl Cyclase Inhibition in Ameliorating Inflammatory Vascular Remodeling in Pulmonary Arterial Hypertension
National Institutes of Health · NATIONAL INSTITUTE OF HEALTH NIH-OD
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N98026R00085 in this department, oldest first.
- Jun 4, 2026Sources SoughtOpen
- Sep 14, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
The National Institutes of Health (NIH) intends to negotiate on a sole-source basis with the University of Illinois at Chicago (UIC) for preclinical animal research services to evaluate the therapeutic effects of soluble adenylyl cyclase (sAC) inhibition on pulmonary arterial hypertension (PAH) using an established endothelial cell-specific Cav1 knockout (EC-Cav1 KO) murine model and corresponding wild-type controls. The Government intends to solicit from a single source pursuant to FAR 13.106-1(b)(1). UIC currently maintains the established EC-Cav1 KO mouse colony required for this study, and… (show all)
the model is not known to be maintained by another laboratory. This notice of intent is not a request for competitive quotations. However, all responsible sources that believe they can satisfy the Government's requirements may submit a capability statement and/or quotation for consideration by the Government. Please see the attached Notice of Intent to Sole Source for the complete description of the requirement, basis for the intended sole-source acquisition, response instructions, and applicable response deadline.
Who won similar work
58 award notices on SAM.gov in the last 24 months. Match: Same agency (National Institutes of Health), same NAICS 541715.
| Winner | Awards | Value | Last |
|---|---|---|---|
| DUKE UNIVERSITY Durham NC 27705 USA | 2 | $36.3M | Mar 31, 2025 |
| The TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 USA | 2 | $17.1M + 1 shared | Sep 25, 2026 |
| Northwestern University 750 N. LAKE SHORE DRIVE RUBLOFF 7TH FLOOR CHICAGO IL 60611 USA | 2 | $7.7M + 1 shared | Apr 10, 2025 |
| WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD. Winston Salem NC 27157 USA | 2 | $4.9M + 1 shared | Apr 10, 2025 |
| SCIOME LLC | 1 | $79.3M | Aug 27, 2026 |
| UNIVERSITY OF MISSISSIPPI MEDICAL CENTER Jackson MS 39216 USA | 1 | $63.9M | Sep 15, 2025 |
| TEMPUS AI, INC · $TEM | 1 | $60.6M | Sep 17, 2025 |
| UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE BOX 359472 Seattle WA 98195 USA | 1 | $55.5M | Apr 10, 2025 |
| WAKE FOREST UNIVERSITY HEALTH SCIENCES Winston Salem NC 27157 USA | 1 | $49.5M | Sep 15, 2025 |
| FISHER BIOSERVICES INC | 1 | $48.0M | Oct 7, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in.
- Oct 7, 2026AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026ADVANCED BIOSCIENCE LABORATORIES, INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026BCG FEDERAL CORP.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026SIA PARTNERS U.S., INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026FISHER BIOSERVICES INC$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026PPD DEVELOPMENT LP$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Sep 28, 2026EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR MAILSTOP 1599-001-1BA Atlanta GA 30322 USA$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation Study
- Sep 28, 2026Versiti Blood Health, Inc.$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation Study
- Sep 25, 2026WESTAT, INC.$21.4MA--REDS-V-Data Coordinating Center
- Sep 25, 2026The TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 USA$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation Study
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards.
- 1 of the past winners are listed companies
- 0 insider buys and 21 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.